Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment

References

• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi:10.1038/35888
   PubMed Web of Science ®Google Scholar
• Quon K, Kassner PD. RNA interference screening for the discovery of oncology targets. Expert Opin Ther Targets. 2009;13(9):1027–1035.
   PubMed Web of Science ®Google Scholar
• Freeman EC, Weiland LM, Meng WS. Modeling the proton sponge hypothesis: examining proton sponge effectiveness for enhancing intracellular gene delivery through multiscale modeling. J Biomater Sci Polym Ed. 2013;24(4):398–416.
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13(6):541–552.
   PubMed Web of Science ®Google Scholar
• Heidi L. Gene-silencing technology gets first drug approval after 20-year wait. Nature. 2018;1:45.
   Google Scholar
• Haupenthal J, Baehr C, Kiermayer S, Zeuzem S, Piiper A. Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol. 2006;71(5):702–710.
   PubMed Web of Science ®Google Scholar
• Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010;28(4):181–188.
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967–977.
   PubMed Web of Science ®Google Scholar
• Santo D, Mendonça PV, Lima MS, Cordeiro RA. Poly(ethylene glycol)- block-poly(2-aminoethyl methacrylate hydrochloride)-Based Polyplexes as Serum-Tolerant Nanosystems for Enhanced Gene Delivery. Int J Med. 2019;16(5):2129–2141.
   Google Scholar
• Shrivats AR, Hsu E, Averick S, et al. Cationic Nanogel-mediated Runx2 and Osterix siRNA Delivery Decreases Mineralization in MC3T3 Cells. Clin Orthop Relat Res. 2015;473(6):2139–2149. doi:10.1007/s11999-014-4073-0
   PubMed Web of Science ®Google Scholar
• Siegwart DJ, Whitehead KA, Nuhn L, et al. Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery. Proc Natl Acad Sci U S A. 2011;108(32):12996–13001. doi:10.1073/pnas.1106379108
   PubMed Web of Science ®Google Scholar
• Averick SE, Paredes E, Dey SK, et al. Autotransfecting short interfering RNA through facile covalent polymer escorts. J Am Chem Soc. 2013;135(34):12508–12511. doi:10.1021/ja404520j
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2(8):469–478.
   PubMed Web of Science ®Google Scholar
• von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS. Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends Biotechnol. 2017;35(2):159–171.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664.
   PubMed Web of Science ®Google Scholar
• Arvizo RR, Miranda OR, Moyano DF, et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011;6(9):e24374.
   PubMed Web of Science ®Google Scholar
• Yue ZG, Wei W, Lv PP, et al. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules. 2011;12(7):2440–2446.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Materials. 2016;1(5):16014.
   Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515.
   PubMed Web of Science ®Google Scholar
• Dash PR, Read ML, Barrett LB, Wolfert MA, Seymour LW. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 1999;6(4):643–650.
   PubMed Web of Science ®Google Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815–823.
   PubMed Web of Science ®Google Scholar
• Riviere K, Kieler-Ferguson HM, Jerger K, Szoka FC. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. J Controlled Release. 2011;153(3):288–296.
   PubMed Web of Science ®Google Scholar
• Subik K, Lee JF, Baxter L, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010;4:35–41.
   PubMedGoogle Scholar
• Akiyoshi K, Deguchi S, Moriguchi N, Yamaguchi S, Sunamoto J. Self-aggregates of hydrophobized polysaccharides in water. Formation and characteristics of nanoparticles. Macromolecules. 1993;26(12):3062–3068.
   Web of Science ®Google Scholar
• Mamot C, Drummond DC, Greiser U, Hong K, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63(12):3154–3161.
   PubMed Web of Science ®Google Scholar
• Martinelli E, Palma RD, Orditura M, Vita FD, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2010;158(1):96.
   Web of Science ®Google Scholar
• Park JH, Seo JH, Jeon HY, et al. Lentivirus-mediated VEGF knockdown suppresses gastric cancer cell proliferation and tumor growth in vitro and in vivo. Angewandte Chem Int Edition. 2020;13:1331–1341.
   Google Scholar
• Ge YL, Zhang X, Zhang JY, Hou L, Tian RH. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol. 2009;9(4):389–395.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang ZR, Zhao N. VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway. Cell Biochem Biophys. 2015;73(2):519.
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666.
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2013;125(23):5591–5596.
   Web of Science ®Google Scholar
• Sriraman SK, Aryasomayajula B, Torchilin VP. Barriers to drug delivery in solid tumors. Tissue Barriers. 2014;2:e29528.
   PubMedGoogle Scholar
• Duan X, Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small. 2013;9(9–10):1521–1532.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fan H, Levorse DA, Crocker LS. Interaction of cholesterol-conjugated ionizable amino lipids with biomembranes: lipid polymorphism, structure-activity relationship, and implications for siRNA delivery. Langmuir. 2011;27(15):9473–9483.
   PubMed Web of Science ®Google Scholar
• Boussif O. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92(16):7297–7301.
   PubMed Web of Science ®Google Scholar
• Pradny M, Kopeeek J. Hydrogels for site-specific oral delivery poly [(acrylic acid)-co-(butyl acrylate)] cross-linked with 4, 4bis (methacrsloylamino) azobenzene. MakromolekuelareChemie Macromolecular Chem Phvs. 1990;191(8):1887–1897.
   Web of Science ®Google Scholar
• Siegel RA, Firestone BA. pH-dependent equilibrium swelling properties of hydrophobic polyelectrolyte copolymer gels. Macromolecules. 1988;21:3254–3259.
   Web of Science ®Google Scholar
• Duan S, Yuan W, Fei W, Jin T. Polyspermine Imidazole‐4,5‐imine, a Chemically Dynamic and Biologically Responsive Carrier System for Intracellular Delivery of siRNA. Angewandte Chem Int Edition. 2021;51(32):7938–7941.
   Web of Science ®Google Scholar
• Henriksen L, Grandal MV, Knudsen SL, van Deurs B, Grøvdal LM. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS One. 2013;8(3):e58148.
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24(3):179–191.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290.
   PubMed Web of Science ®Google Scholar
• Petrul HM, Schatz CA, Kopitz CC, et al. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012;11(2):340–349.
   PubMed Web of Science ®Google Scholar
• Fabricius EM, Wildner GP, Kruse-Boitschenko U, Hoffmeister B, Goodman SL, Raguse JD. Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med. 2011;2(1):9–19.
   PubMed Web of Science ®Google Scholar
• Tenzer S, Docter D, Kuharev J, et al. Rapid formation of plasma protein Corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772–781.
   PubMed Web of Science ®Google Scholar
• Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule Corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137–143.
   PubMed Web of Science ®Google Scholar
• Pribluda A, de la Cruz CC, Jackson EL. Intratumoral Heterogeneity: from Diversity Comes Resistance. Clin Cancer Res. 2015;21(13):2916–2923.
   PubMed Web of Science ®Google Scholar
• Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234(5):5628–5642.
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–622.
   PubMed Web of Science ®Google Scholar
• Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(Pt 24):4195–4200.
   PubMed Web of Science ®Google Scholar
• Heldin C-H, Rubin K, Pietras K, Östman A. High interstitial fluid pressure — an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–813.
   PubMed Web of Science ®Google Scholar
• Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441–1454.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205–2218.
   PubMed Web of Science ®Google Scholar
• Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004;64(10):3365–3370.
   PubMed Web of Science ®Google Scholar
• Jia RB, Zhang P, Zhou YX, et al. VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res. 2007;39(2):108–115.
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Goel S, Kamoun WS, et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci U S A. 2011;108(9):3725–3730.
   PubMed Web of Science ®Google Scholar